The use of an agency-approved animal source for the company's cell line is part of the company's regulatory strategy ahead of the planned approval process in the U.S.

The new product is a result of the company’s recently filed patent for 3D-bioprinting technology that allows unprecedented marbling control within a consolidated structure.

The new induced pluripotent porcine stem cell line enables the company to continue diversifying its species portfolio and accelerate its market readiness for cultured pork production.

The new name reflects the company's commitment to cultivating a new community of meat lovers who will participate in the company's mission to make high-quality real meat sustainably.